Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 17 clinical trials
[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma

FES PET/CT imaging for invasive lobular cancer

  • 0 views
  • 14 Jul, 2022
  • 1 location
Well-Being After Breast Cancer Surgery (WB ABCs)

breast surgery for lobular carcinoma in situ (LCIS), ductal carcinoma in situ (DCIS), or invasive breast cancer, and to examine the roles of psychological and physiological variables as modifiable

  • 0 views
  • 07 Jul, 2022
  • 2 locations
No Axillary sUrgical Treatment In Clinically Lymph Node Negative Patients After UltraSonography

NAUTILUS study is a prospective, multicenter, RCT. Clinically T1,T2, node negative BCS candidates with no evidence of metastases in AUS are 1:1 randomized into no SLNB group and SLNB group. NAUTILUS study aim to establish the minimally invasive treatment of breast cancer by reexamining the necessity of sentinel lymph node …

breast carcinoma
metastasis
sentinel node
invasive breast cancer
carcinoma
  • 0 views
  • 13 Apr, 2021
  • 1 location
Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk Breast Ductal Carcinoma in Situ

Although the results obtained from ECOG E5194 cohort 1 (criteria: mammographically detected low- or intermediate-grade DCIS, measuring less than 2.5 cm with margins 3 mm) and RTOG 9804 trial (the same enrolled clinicopathological features to cohort 1 of ECOG E5194 trial) demonstrated that the 7-year ipsilateral breast tumor recurrence (IBTR) …

estrogen receptor
radiotherapy to breast
carcinoma in situ
estrogen
breast tumor
  • 18 views
  • 14 Feb, 2022
  • 1 location
Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ

The investigators plan to prospectively study breast tissue changes after a short course of Tamoxifen (Tam).

  • 2 views
  • 26 Sep, 2021
  • 1 location
Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE) (ROSALINE)

Despite different clinical characteristics including the response to treatment and the patterns of metastatic relapse, invasive lobular breast carcinoma (ILBC) is treated like invasive ductal breast carcinoma (IDBC) carcinoma both in the clinics and in clinical trials. A large majority of ILBC are ER+/HER2- and almost 90% have loss of …

  • 0 views
  • 26 May, 2022
  • 10 locations
Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer

This phase I trial studies how well fluciclovine positron emission tomography (PET)/computed tomography (CT) and PSMA PET/CT work in helping doctors understand and classify invasive lobular breast cancer in patients with invasive lobular breast cancer that is suspicious for or has spread to other places in the body (metastasized). Fluciclovine …

  • 0 views
  • 04 Oct, 2022
  • 1 location
Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)

This trial studies the implementation of web-based decision support tools for patients with atypical hyperplasia or lobular carcinoma in situ and healthcare providers. Decision support tools are

Accepts healthy volunteers
  • 0 views
  • 23 Mar, 2022
  • 19 locations
Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours (ROLo)

The purpose of this study is to find out how effective the combination of crizotinib and fulvestrant is in shrinking lobular breast cancer tumours. The investigators will also be assessing the side effects of the combination of crizotinib tablets and fulvestrant injections. The side effects and the doses of crizotinib …

cancer chemotherapy
fulvestrant
CDH1
mammogram
measurable disease
  • 6 views
  • 09 Feb, 2022
  • 5 locations
Ruxolitinib for Premalignant Breast Disease (TBCRC042)

This study is evaluating how ruxolitinib affects premalignant breast cells. One half of the study participants will receive ruxolitinib for approximately 15 days, and the other half will receive a placebo (sugar pill) for approximately 15 days. Once study participants have completed their ruxolitinib or placebo, participants will undergo surgery …

carcinoma in situ
neutrophil count
atypical ductal hyperplasia
ductal hyperplasia
clarithromycin
  • 49 views
  • 23 May, 2022
  • 7 locations